Status:
NOT_YET_RECRUITING
The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory
Lead Sponsor:
Nicola Irwin
Conditions:
Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus Hospitalizations
Eligibility:
All Genders
Up to 2 years
Brief Summary
The goal of this observational study is to is to examine the impact of new RSV prevention medicines on the burden of RSV disease among young children. The main question it aims to answer is: What was...
Detailed Description
Nirsevimab, a novel long-acting monoclonal antibody targeted at RSV became available for vulnerable babies in the Australian Capital Territory (a small jurisdiction in Australia) in April 2024. Matern...
Eligibility Criteria
Inclusion
- child aged under 2 years
- laboratory confirmed RSV
Exclusion
- n/a
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT07164430
Start Date
September 1 2025
End Date
December 1 2025
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Canberra Hospital
Garran, Australian Capital Territory, Australia, 2605